| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/20/2013 | US20130158104 Vectors and sequences for the treatment of diseases |
| 06/20/2013 | US20130158103 Method of Tissue-Selective Targeted Gene Transfer |
| 06/20/2013 | US20130157357 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 06/20/2013 | US20130157263 Methods and compositions for seamless cloning of nucleic acid molecules |
| 06/20/2013 | US20130156849 Modified nucleoside, nucleotide, and nucleic acid compositions |
| 06/20/2013 | US20130156794 Immunotherapy using redirected allogeneic cells |
| 06/20/2013 | US20130156775 Chlamydia trachomatis antigens |
| 06/20/2013 | US20130156736 Complementing cell lines |
| 06/20/2013 | US20130156729 Mammalian Receptor Proteins; Related Reagents and Methods |
| 06/19/2013 | EP2604689A1 Anti-obesity agent and anti-obesity food |
| 06/19/2013 | EP2604621A1 Method and Carrier Complexes for Delivering Molecules to Cells |
| 06/19/2013 | EP2604287A2 Method and Carrier Complexes for Delivering Molecules to Cells |
| 06/19/2013 | EP2604286A1 Method and Carrier Complexes for Delivering Molecules to Cells |
| 06/19/2013 | EP2604285A1 Method and Carrier Complexes for Delivering Molecules to Cells |
| 06/19/2013 | EP2603238A1 Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| 06/19/2013 | CN103168101A Genome editing using targeting endonucleases and single-stranded nucleic acids |
| 06/19/2013 | CN103167883A Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| 06/19/2013 | CN103167866A Novel low molecular weight cationic lipids for oligonucleotide delivery |
| 06/19/2013 | CN103160557A Purpose of ribosomal protein S5 in catalyzing of protein molecules for generatation of dephosphorylation reaction |
| 06/19/2013 | CN103160538A Virus with surface modified with calcium phosphate and preparing method of virus |
| 06/19/2013 | CN103160530A Fusion gene and applications thereof |
| 06/19/2013 | CN103160520A MiR-15a target site sequence and application of miR-15a target site sequence in restraining hepatitis B virus replication |
| 06/19/2013 | CN103159836A Compound biological agent for blocking human immunodeficiency virus (HIV) viruses from being replicated and being integrated with deoxyribonucleic acid (DNA) of host cell |
| 06/19/2013 | CN103159832A Peptide with neuroprotective effect, preparation method thereof, pharmaceutical composition and purpose |
| 06/19/2013 | CN103157117A Medicine for regulating and controlling TRAIL (Tnf (Tumor necrosis factor) Related Apoptosis Inducing Ligand) tolerance of tumour |
| 06/19/2013 | CN103157116A Novel cancer suppressor gene UNC5D and new applications of encoded protein thereof |
| 06/19/2013 | CN103157115A Application of human RHBDD1 gene and drugs related to gene |
| 06/19/2013 | CN103157114A Purposes and related medicines of human ZNF786 gene |
| 06/19/2013 | CN103157113A Chimeric type DNA vaccine HSP70/CD80 for asthma prevention and immunotherapy |
| 06/19/2013 | CN103157109A CD146 and antibody diagnosis thereof, and application in treating triple negative breast cancer |
| 06/19/2013 | CN102319440B Preparation method of porcine parvovirus genetic engineering vaccine |
| 06/19/2013 | CN102260698B PTA-linker-thanatin fusion protein expressed in escherichia coli, and anticancer research thereof |
| 06/19/2013 | CN102257138B Tumor antigen peptide and use thereof |
| 06/19/2013 | CN102070712B VEGF-A (vascular endothelial growth factor-A) protein and use thereof |
| 06/19/2013 | CN101914533B Interfering rna duplex having blunt-ends and 3'-modifications |
| 06/19/2013 | CN101838611B Recombinant plasmodium for expressing exogenous gene and application thereof |
| 06/19/2013 | CN101466835B Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 06/18/2013 | US8466274 RNAi therapeutic for treatment of hepatitis C infection |
| 06/18/2013 | US8466267 Nucleic acid encoding a zinc finger that recognizes the sodium channel Nav 1.8 (PN3) gene |
| 06/18/2013 | US8466124 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 06/18/2013 | US8466123 Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer |
| 06/18/2013 | US8466120 Oligomeric compounds and compositions for use in modulation of pri-miRNAs |
| 06/18/2013 | US8466117 Compositions and methods for modulating angiogenesis |
| 06/18/2013 | US8466116 Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| 06/18/2013 | US8465750 Staphylococcus aureus proteins and nucleic acids |
| 06/18/2013 | US8465732 Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof |
| 06/18/2013 | CA2522669C Postnatal stem cells and uses thereof |
| 06/18/2013 | CA2438273C Tryptophanyl-trna synthetase derived polypeptides useful for the regulation of angiogenesis |
| 06/13/2013 | WO2013086515A1 Compositions and methods for the prevention or treatment of diabetic complications |
| 06/13/2013 | WO2013086125A2 Method of inducing immune tolerance through targetted gene expression |
| 06/13/2013 | WO2013086031A1 Method of therapy selection for patients with cancer |
| 06/13/2013 | WO2013086008A1 Methods and products for transfecting cells |
| 06/13/2013 | WO2013085483A1 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions |
| 06/13/2013 | WO2013084001A1 Exosomes with transferrin peptides |
| 06/13/2013 | WO2013083063A1 Hsp70/cd80 chimeric dna vaccine for use in asthma prevention and immunotherapy |
| 06/13/2013 | WO2013056132A3 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| 06/13/2013 | WO2013051900A3 Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof |
| 06/13/2013 | WO2013042125A8 Nano delivery systems |
| 06/13/2013 | WO2013041692A3 Method to predict the presence of inflammation or itaconic acid, irg1 and/or protein irg1 in a subject and pharmaceutical composition for treating or preventing inflammation |
| 06/13/2013 | WO2013025064A3 Anti-cancer composition comprising wnt decoy receptors |
| 06/13/2013 | WO2012170664A3 Methods of cancer treatment and prevention through the modulation of sirt4 activity |
| 06/13/2013 | WO2012125987A9 Delivery system |
| 06/13/2013 | US20130150570 Nuclease resistant double-stranded ribonucleic acid |
| 06/13/2013 | US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents |
| 06/13/2013 | US20130149371 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
| 06/13/2013 | US20130149337 Method of controlling administration of cancer antigen |
| 06/13/2013 | US20130149334 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/13/2013 | CA2858148A1 Methods and products for transfecting cells |
| 06/12/2013 | EP2602326A1 Methods for transfecting nucleic acids into live cells |
| 06/12/2013 | EP2602322A1 Induction of exon skipping in eukaryotic cells |
| 06/12/2013 | EP2601971A1 Composition for regeneratng normal tissue from fibrotic tissue |
| 06/12/2013 | EP2601932A1 Lyophilized recombinant VWF formulations |
| 06/12/2013 | EP2600901A2 Engineered nucleic acids and methods of use thereof |
| 06/12/2013 | EP2600900A2 Multiplexed supramolecular assemblies for non-viral delivery of genetic material |
| 06/12/2013 | EP2600897A2 Methods and compositions for the inhibition of fructokinase |
| 06/12/2013 | EP2600896A2 Treating breast cancer with anti-il-19 antibody |
| 06/12/2013 | EP2600891A2 Protein fusion constructs possessing thrombolytic and anticoagulant properties |
| 06/12/2013 | CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/12/2013 | CN1922332B Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 06/12/2013 | CN1529753B Disease-associated protein |
| 06/12/2013 | CN103154272A Methods and kits for predicting the risk of diabetes associated complications using genetic markers and arrays |
| 06/12/2013 | CN103154014A Modified nucleosides and oligomeric compounds prepared therefrom |
| 06/12/2013 | CN103153347A Novel low molecular weight cationic lipids for oligonucleotide delivery |
| 06/12/2013 | CN103153346A Methods of treatment using tlr7 and/or tlr9 inhibitors |
| 06/12/2013 | CN103153344A Methods, compositions, and kits for the treatment of matrix mineralization disorders |
| 06/12/2013 | CN103146705A siRNA (Small interfering Ribose Nucleic Acid) for silencing seps1 (selenoprotein s1) gene of mice |
| 06/12/2013 | CN103146703A siRNA for inhibiting growth of epithelial ovarian cancer as well as recombinant vector and application thereof |
| 06/12/2013 | CN103146702A Application of MiR-181a-5p in non-small cell lung cancer |
| 06/12/2013 | CN103146689A Short hairpin ribonucleic acid (shRNA) and shRNA application to preparation of medicines for curing colorectal cancer |
| 06/12/2013 | CN103146626A Genetically engineered bacterium for treating breast cancer and construction method and application |
| 06/12/2013 | CN103145976A Compound for cell targeting gene vector and use thereof |
| 06/12/2013 | CN103145849A Chimeric antigen receptor and its use |
| 06/12/2013 | CN103145822A Fish natural killer (NK)-lysin effective factors and application method thereof |
| 06/12/2013 | CN103145802A Polypeptide infection promoting agent |
| 06/12/2013 | CN103143034A Recombinant vaccine against bluetongue virus |
| 06/12/2013 | CN103143033A Targeting liver cell carrier and preparation method thereof |
| 06/12/2013 | CN103143032A Recombinant plasmid vaccine for treating hepatitis B and composition thereof |
| 06/12/2013 | CN103143017A VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| 06/12/2013 | CN103143005A Application of polypeptide with LACK antigen Th2-type epitope in preparing medicine for preventing and treating autoimmune disease |
| 06/12/2013 | CN102552924B Application of neutral dendritic polymer material to preparing drug carrier |